文献速递免疫规划卫生政策与健康促进慢病防控与筛查

阿富汗二价人乳头瘤病毒(HPV)疫苗接种的潜在健康影响与成本效果

Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan.
PubMed 文献 · Vaccine · 2019-12-20

本研究使用Excel静态队列模型评估阿富汗2018年9岁女孩单剂次二价HPV疫苗接种相对于不接种的终身成本与健康结局,并探索10-14岁女孩补接种场景。结果显示单队列接种可避免1718例宫颈癌、125例住院和1612例死亡,增量成本效果比为政府视角每避免一个伤残调整生命年(DALY)426美元、社会视角400美元,结论为具有潜在成本效果(0.7倍人均GDP 586美元)。

要点

  • 阿富汗9岁女孩单队列接种二价HPV疫苗可避免1718例宫颈癌、125例住院和1612例死亡。
  • 增量成本效果比:政府视角每避免一个DALY 426美元,社会视角400美元。
  • HPV疫苗接种项目年成本约3,343,311美元,占2018年免疫预算3.53%或卫生总支出0.13%。

核心结论

  • 在阿富汗,针对单队列的HPV疫苗引入从政府和社会视角均具有潜在成本效果(0.7倍人均GDP 586美元),补接种活动可产生额外健康获益,取决于政府对预期健康结局的支付意愿。

研究设计与样本

  • 使用Excel静态队列模型估算2018年9岁女孩单队列接种二价HPV疫苗相对于不接种的终身成本与健康结局,并探索10-14岁女孩补接种场景。
  • 输入参数基于当地来源、已发表文献或无可获得数据时的假设。
  • 主要结局指标为从政府和社会视角评估的每避免一个DALY的贴现成本。

主要发现

  • 单队列9岁女孩接种HPV疫苗可在队列终身避免1718例宫颈癌、125例住院和1612例死亡。
  • 增量成本效果比为政府视角每避免一个DALY 426美元,社会视角每避免一个DALY 400美元。
  • HPV疫苗接种项目年成本估计为3,343,311美元,约占2018年全国免疫预算的3.53%或卫生总支出的0.13%。

关键数值与推荐

  • 增量成本效果比:政府视角每避免一个DALY 426美元;社会视角每避免一个DALY 400美元。
  • 成本效果阈值参考:0.7倍人均GDP 586美元。
  • 年项目成本3,343,311美元占2018年免疫预算3.53%、卫生总支出0.13%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Human papillomavirus (HPV) vaccination has not been introduced in many countries in South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV vaccination in Afghanistan to inform national decision-making. METHOD: An Excel-based static cohort model was used to estimate the lifetime costs and health outcomes of vaccinating a single cohort of 9-year-old girls in the year 2018 with the bivalent HPV vaccine, compared to no vaccination. We also explored a scenario with a catch-up campaign for girls aged 10-14 years. Input parameters were based on local sources, published literature, or assumptions when no data was available. The primary outcome measure was the discounted cost per disability-adjusted life-year (DALY) averted, evaluated from both government and societal perspectives. RESULTS: Vaccinating a single cohort of 9-year-old girls against HPV in Afghanistan could avert 1718 cervical cancer cases, 125 hospitalizations, and 1612 deaths over the lifetime of the cohort. The incremental cost-effectiveness ratio was US$426 per DALY averted from the government perspective and US$400 per DALY averted from the societal perspective. The estimated annual cost of the HPV vaccination program (US$3,343,311) represents approximately 3.53% of the country's total immunization budget for 2018 or 0.13% of total health expenditures. CONCLUSION: In Afghanistan, HPV vaccine introduction targeting a single cohort is potentially cost-effective (0.7 times the GDP per capita of $586) from both the government and societal perspective with additional health benefits generated by a catch-up campaign, depending on the government's willingness to pay for the projected health outcomes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Anwari P, Debellut F, Vodicka E, et al. Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan. Vaccine. 2019. PMID: 31870571. doi:10.1016/j.vaccine.2019.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。